Previous 10 | Next 10 |
Arlington Asset Investment (NYSE: AI ) -21% after suspending Q1 dividend. More news on: Arlington Asset Investment Corp., BGC Partners, Inc., Altimmune, Inc., Stocks on the move, , Read more ...
Arbutus Biopharma (NASDAQ: ABUS ) announces positive preliminary results from a Phase 1a/1b clinical trial (AB-729-001) in healthy subjects and two cohorts of chronic hepatitis B subjects on nucleos(t)ide antiviral therapy, all of whom received a single subcutaneous injection of AB-729. ...
Positive single dose AB-729 data in chronic hepatitis B subjects supports further clinical development First multiple dose cohort results expected in second half of 2020 One or more additional single dose cohorts planned to further optimize antiviral response and dosing fre...
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Buy rating and $69 (55% upside) price target at Citigroup. More news on: ACADIA Pharmaceuticals Inc., Alector, Inc., GW Pharmaceuticals plc, Healthcare stocks news, , Stocks on the move, Read more ...
WARMINSTER, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its fourth quarter and Year-End 2019 financial results, conference call and webcast for Thursday, M...
Brickell Biotech (NASDAQ: BBI ) +64% on positive sofpironium bromide data. More news on: Brickell Biotech, Inc., Adesto Technologies Corporation, Stamps.com Inc., Stocks on the move, Read more ...
Based on findings from preclinical studies, Arbutus Biopharma (NASDAQ: ABUS ) has decided not to advance AB-452, its first-generation oral hepatitis B-specific RNA destabilizer, opting instead to continue development of its next-generation candidate. More news on: Arbutus Biopharma Corpo...
Myomo (NYSEMKT: MYO ) -19% . More news on: Myomo, Inc., Arbutus Biopharma Corporation, Biohaven Pharmaceutical Holding Company Ltd., Stocks on the move, , Read more ...
Myomo (NYSEMKT: MYO ) +93% on insurance coverage of MyoPro in Germany. More news on: Myomo, Inc., VIVUS, Inc., Camber Energy, Inc., Stocks on the move, , Read more ...
ICAD (NASDAQ: ICAD ) initiated with Market Perform rating and $15 (163% upside) price target at JMP Securities. More news on: iCAD, Inc., National Health Investors, Inc., Sabra Health Care REIT, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...